Recently, the boron neutron capture therapy (BNCT) system introduced to the Boron Neutron Tumor Treatment Center at Huzhou Hospital Affiliated to Zhejiang University School of Medicine, the first of its kind in Zhejiang Province, has drawn attention. Prior to this, the system has initiated a Phase I BNCT "drug-device combination" clinical trial.

According to the system's developer, Huaboron Neutron Technology (Hangzhou) Co., Ltd., BNCT is a radiopharmaceutical combination therapy technology, the core of which lies in the combined use of boron-containing drugs and neutron irradiation. After the boron-containing drug enters the human body, it can be absorbed by tumor cells; subsequent neutron beam irradiation then triggers a localized reaction, achieving targeted radiotherapy against cancer cells.

Unlike conventional radiotherapy, which typically employs fractionated irradiation and longer treatment courses, BNCT emphasizes selective targeting of tumor cells, with the goal of reducing damage to surrounding healthy tissue and minimizing radiotherapy-related side effects such as hair loss and decreased immunity. Relevant personnel noted that head and neck cancer has currently been incorporated into BNCT clinical applications internationally, and expansion studies for indications including glioblastoma, melanoma, breast cancer, and lung cancer are also underway.

It is understood that the Huzhou BNCT treatment system is mainly composed of an accelerator subsystem and a treatment subsystem. The accelerator subsystem is responsible for generating the neutrons required for treatment and is the key component of the system; the treatment subsystem undertakes functions such as image guidance, dose monitoring, and treatment control, ensuring precise execution of the treatment process.

Currently, this Phase I clinical study is proceeding according to the trial protocol, with the clinical team continuously monitoring treatment response and safety data in enrolled patients. The project is still recruiting eligible patients from the public to further complete clinical validation.

Source link: https://www.cinie.net/article/62949.html

This information is for industry reference only. Copyright belongs to the original platform. Please contact us for removal if there are any copyright issues.